Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: 2 | Rare Historical Photos

Is Wall Street Bullish or Bearish on Viatris' Stock?

Viatris has underperformed the broader market over the past year, and Wall Street analysts are cautious about the stock’s prospects.

Barchart

Viatris Quarterly Earnings Preview: What You Need to Know

Viatris is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.

Barchart

3 Low P/E Stocks With Strong Growth Prospects

With easing inflation and possibilities of interest rate cuts, investors can rely on stocks like Viatris (VTRS), Open Text (OTEX), and Goodyear Tire & Rubber (GT) with strong growth prospects, trading at affordable prices. Keep reading.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Pharmaceutical Stocks With Blockbuster Potential

The pharmaceutical industry’s long-term growth is fueled by a surge in demand for personalized medicine, favorable R&D initiatives, and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid pharma stocks Zoetis (ZTS), Viatris (VTRS), and Bristol-Myers Squibb (BMY) poised for blockbuster return potential. Keep reading….

StockNews.com

4 Pharma Stocks to Watch for Surprising Gains in June

Amid growing demand for specialty drugs and increasing adoption of emerging technology in pharmaceutical manufacturing, the pharma industry is witnessing steady expansion. Therefore, quality pharmaceutical stocks Zoetis (ZTS), Viatris (VTRS), MEI Pharma (MEIP), and Amphastar Pharmaceuticals (AMPH) could be ideal additions to your watchlist. Keep reading….

StockNews.com

Are Wall Street Analysts Bullish on Viatris Stock?

Viatris has underperformed the broader market over the past year, and analysts remain cautious about the stock's prospects.

Barchart

3 Top-Rated Pharma Stocks to Diversify Your Portfolio

The pharmaceutical industry is expanding owing to the rising incidence of chronic diseases, increasing investments in R&D, and the use of advanced technologies for drug development and manufacturing. Given this backdrop, investors could consider buying quality pharma stocks such as Elanco Animal Health (ELAN), Viatris (VTRS), and Astellas Pharma (ALPMY),…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Pharma Stocks Outperforming the Competition

The growing demand for innovative drugs, the use of advanced technologies, and growing global healthcare needs boost the pharmaceutical industry’s long-term growth prospects. Therefore, fundamentally strong pharma stocks Viatris (VTRS), Wave Life Sciences (WVE), and MEI Pharma (MEIP) might be ideal additions to your portfolio. Read on.

StockNews.com

5 Pharma Stocks to Watch With Bullish Momentum

The pharma industry is poised for robust expansion this year with rising demand and technological advancement in the sector. Hence, investors might watch fundamentally solid pharma stocks Procaps Group (PROC), Sanofi (SNY), Viatris (VTRS), Ipsen (IPSEY), and Teva Pharmaceutical Industries (TEVA) for solid gains. Read on.

StockNews.com

3 Lucrative Pharma Stocks for Portfolio Success

The pharmaceutical industry holds immense promise due to the rapidly aging population, growing healthcare needs, breakthroughs in new drugs and therapies, and the rise in chronic diseases. Therefore, it could be wise to add fundamentally strong pharma stocks Supernus Pharmaceuticals (SUPN), Eton Pharmaceuticals (ETON), and Viatris (VTRS) to one’s portfolio.…

StockNews.com

Top 4 Pharma Picks for January 2024 Growth

The pharmaceutical industry’s future is increasingly promising, spurred by a rise in healthcare expenditure amid escalating chronic and rare disease cases and a burgeoning aged population. The industry's bright outlook is also strengthened by consistent forays into research and development. Against this backdrop, quality pharma stocks Pacira BioSciences (PCRX), Eli…

StockNews.com

Under $15 Bargains: 3 Pharma Stocks to Watch

The pharmaceutical industry is anticipated to remain resilient, owing to increasing healthcare expenditure. Given this backdrop, it could be wise to watch quality pharma stocks Organon & Co. (OGN), GoodRx Holdings (GDRX), and Viatris (VTRS) trading under $15 now. Read on….

StockNews.com

3 Stocks to Buy With Less Than $10

The recent collapse of two banks and growing uncertainty about the Fed’s next rate hike amid the strong economic data releases fueled a broad market sell-off lately. However, a volatile market environment offers an attractive opportunity to invest in quality stocks ADT (ADT), Viatris (VTRS), and trivago (TRVG) at reasonable…

StockNews.com

Viatris Posts Q1 Profit Despite 5% Dip In Sales, Reiterates FY22 Guidance Above Consensus

Viatris Inc (NASDAQ:VTRS) reported Q1 FY22 sales of $4.18 billion, down 5% Y/Y (-1% on an operational basis), below the consensus of $4.23 billion. Brands performed better than expectations, such as Lipitor, Effexor, and Perforomist. Complex generics and biosimilars grew by 21% Y/Y on an operational basis, driven mainly by the generic…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Viatris Q1 2022 Earnings Conference Call On May 9, 2022 At 08:30 AM ET

Viatris (NASDAQ:VTRS) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results.

Benzinga

Viatris' Mylan Recalls One Batch Of Insulin Glargine Due To Missing Label

Mylan Pharmaceuticals Inc, a Viatris Inc (NASDAQ: VTRS) company, is

Benzinga

Viatris's Return On Capital Employed Overview

Benzinga Pro data, Viatris (NASDAQ:VTRS) reported Q4 sales of $4.34 billion. Earnings fell to a loss of $263.80 million, resulting in a 184.69% decrease from last quarter. Viatris earned $311.50 million, and sales totaled $4.54 billion in Q3.

Benzinga

Why Viatris Shares Are Trading Lower Today

Viatris Inc (NASDAQ: VTRS) is trading lower Monday after the company reported worse-than-expected top-line results for the fourth quarter and issued guidance below estimates.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Viatris To Pay $264M As EpiPen Antitrust Litigation Settlement: Reuters

Viatris Inc (NASDAQ: VTRS), previously known as Mylan, has

Benzinga

India-Based Biocon To Buy Viatris' Biosimilars Assets In $3.3B Deal

Biocon Biologics Ltd has agreed to acquire Viatris Inc's (NASDAQ:VTRS) biosimilars assets for up to $3.335 billion in stock and cash. The deal value includes cash of up to $2.335 billion and Compulsorily Convertible Preference Shares in Biocon Biologics, valued at $1 billion. Viatris will also pay $50 million to Biocon Biologics to fund…

Benzinga

A Bullish Sign Appears On Viatris's Chart

If history is any guide, there may be good fortune ahead for shares of Viatris (NASDAQ:VTRS). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Benzinga

Viatris Recalls One Batch Of Diabetes Treatment Semglee Citing Missing Label Risks

Viatris Inc's (NASDAQ: VTRS) Mylan will pull one batch of non-interchangeable Semglee, also known as insulin glargine injection.

1 2

People

Kritika SarmahHer

727 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

BristolMyers Squibb Company

Eli Lilly and Company

62 stories

Viatris

61 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.